Cultured dendritic cells can prime potent cytotoxic t lymphocyte responses to chronic myelogenous leukemia

Rachel M. Syme, Peter Duggan, Tracey Bryan, Doug Stewart, Stefan Gluck

Research output: Contribution to journalArticle

Abstract

Dendritic cells are potent antigen presenting cells, which are integral to the initiation of T cell immunity. The ability to culture these cells in vitro has lead to exciting developments in the area of immunotherapy. We undertook the following study to determine if we could induce CTL responses to CML tumor cells, and then examined ways to improve levels of cytotoxicity. Chronic myelogenous leukemia is one of the first hématologie diseases with a defined cytogenetic marker. Initially we generated DC from PBMC, that were collected for autologous transplantation, by culturing adherent cells in the presence of IL-4 and OM-CSF. After 7 days the resultant dendritic cells were harvested and utilized to prime T cells. In brief, PBMC were stimulated in the presence of dendritic cells pulsed with tumor cell lysate from a CML cell line (SK562). After 7 days the cells were restimulated with another round of dendritic cells and lysate. After a further 7 days the resultant primed cells were harvested, counted and utilized in an LDH based cytotoxicity assay. We found we could generate cytotoxicity (12-75%) at a high (10:1) effector (primed cells) to target (SK562 cells) cell ratio. We were able to improve the level and consistency of cytotoxicity (60-63%) at the same E:T ratios by utilizing either whole protein or RNA from the SK562 cell line as a source of antigen. We were also able to generate appreciable cytotoxicity at lower E:T ratios (25% at 1:1 ), and had improved specificity when the CTL were tested against malignant and non-malignant controls. To further enhance the level of cytotoxicity we tried to increase the immunostimulatory ability of dendritic cells by maturing them. Subsequent to pulsing the cells with tumor lysate they were matured over night in the presence of monocyte conditioned media. At at 1:1 ratio we increased cytotoxicity levels from undetectable to 30-50%. Together this data suggests that we can generate potent cytotoxic responses to CML cells, and that by manipulating the antigen or dendritic cells we can induce responses at very low E:T ratios. These studies are ongoing.

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART II
StatePublished - Dec 1 2000
Externally publishedYes

Fingerprint

Lymphocytes
Cytotoxicity
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Dendritic Cells
Cultured Cells
Emitter coupled logic circuits
Cells
Tumors
T-cells
Antigens
Conditioned Culture Medium
Cell culture
Interleukin-4
T-Lymphocytes
Cell Line
Neoplasms
Assays
Autologous Transplantation
Antigen-Presenting Cells
RNA

ASJC Scopus subject areas

  • Hematology

Cite this

Syme, R. M., Duggan, P., Bryan, T., Stewart, D., & Gluck, S. (2000). Cultured dendritic cells can prime potent cytotoxic t lymphocyte responses to chronic myelogenous leukemia. Blood, 96(11 PART II).

Cultured dendritic cells can prime potent cytotoxic t lymphocyte responses to chronic myelogenous leukemia. / Syme, Rachel M.; Duggan, Peter; Bryan, Tracey; Stewart, Doug; Gluck, Stefan.

In: Blood, Vol. 96, No. 11 PART II, 01.12.2000.

Research output: Contribution to journalArticle

Syme, RM, Duggan, P, Bryan, T, Stewart, D & Gluck, S 2000, 'Cultured dendritic cells can prime potent cytotoxic t lymphocyte responses to chronic myelogenous leukemia', Blood, vol. 96, no. 11 PART II.
Syme RM, Duggan P, Bryan T, Stewart D, Gluck S. Cultured dendritic cells can prime potent cytotoxic t lymphocyte responses to chronic myelogenous leukemia. Blood. 2000 Dec 1;96(11 PART II).
Syme, Rachel M. ; Duggan, Peter ; Bryan, Tracey ; Stewart, Doug ; Gluck, Stefan. / Cultured dendritic cells can prime potent cytotoxic t lymphocyte responses to chronic myelogenous leukemia. In: Blood. 2000 ; Vol. 96, No. 11 PART II.
@article{25d4a1604b8d4b4abbf711887bf157a9,
title = "Cultured dendritic cells can prime potent cytotoxic t lymphocyte responses to chronic myelogenous leukemia",
abstract = "Dendritic cells are potent antigen presenting cells, which are integral to the initiation of T cell immunity. The ability to culture these cells in vitro has lead to exciting developments in the area of immunotherapy. We undertook the following study to determine if we could induce CTL responses to CML tumor cells, and then examined ways to improve levels of cytotoxicity. Chronic myelogenous leukemia is one of the first h{\'e}matologie diseases with a defined cytogenetic marker. Initially we generated DC from PBMC, that were collected for autologous transplantation, by culturing adherent cells in the presence of IL-4 and OM-CSF. After 7 days the resultant dendritic cells were harvested and utilized to prime T cells. In brief, PBMC were stimulated in the presence of dendritic cells pulsed with tumor cell lysate from a CML cell line (SK562). After 7 days the cells were restimulated with another round of dendritic cells and lysate. After a further 7 days the resultant primed cells were harvested, counted and utilized in an LDH based cytotoxicity assay. We found we could generate cytotoxicity (12-75{\%}) at a high (10:1) effector (primed cells) to target (SK562 cells) cell ratio. We were able to improve the level and consistency of cytotoxicity (60-63{\%}) at the same E:T ratios by utilizing either whole protein or RNA from the SK562 cell line as a source of antigen. We were also able to generate appreciable cytotoxicity at lower E:T ratios (25{\%} at 1:1 ), and had improved specificity when the CTL were tested against malignant and non-malignant controls. To further enhance the level of cytotoxicity we tried to increase the immunostimulatory ability of dendritic cells by maturing them. Subsequent to pulsing the cells with tumor lysate they were matured over night in the presence of monocyte conditioned media. At at 1:1 ratio we increased cytotoxicity levels from undetectable to 30-50{\%}. Together this data suggests that we can generate potent cytotoxic responses to CML cells, and that by manipulating the antigen or dendritic cells we can induce responses at very low E:T ratios. These studies are ongoing.",
author = "Syme, {Rachel M.} and Peter Duggan and Tracey Bryan and Doug Stewart and Stefan Gluck",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

TY - JOUR

T1 - Cultured dendritic cells can prime potent cytotoxic t lymphocyte responses to chronic myelogenous leukemia

AU - Syme, Rachel M.

AU - Duggan, Peter

AU - Bryan, Tracey

AU - Stewart, Doug

AU - Gluck, Stefan

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Dendritic cells are potent antigen presenting cells, which are integral to the initiation of T cell immunity. The ability to culture these cells in vitro has lead to exciting developments in the area of immunotherapy. We undertook the following study to determine if we could induce CTL responses to CML tumor cells, and then examined ways to improve levels of cytotoxicity. Chronic myelogenous leukemia is one of the first hématologie diseases with a defined cytogenetic marker. Initially we generated DC from PBMC, that were collected for autologous transplantation, by culturing adherent cells in the presence of IL-4 and OM-CSF. After 7 days the resultant dendritic cells were harvested and utilized to prime T cells. In brief, PBMC were stimulated in the presence of dendritic cells pulsed with tumor cell lysate from a CML cell line (SK562). After 7 days the cells were restimulated with another round of dendritic cells and lysate. After a further 7 days the resultant primed cells were harvested, counted and utilized in an LDH based cytotoxicity assay. We found we could generate cytotoxicity (12-75%) at a high (10:1) effector (primed cells) to target (SK562 cells) cell ratio. We were able to improve the level and consistency of cytotoxicity (60-63%) at the same E:T ratios by utilizing either whole protein or RNA from the SK562 cell line as a source of antigen. We were also able to generate appreciable cytotoxicity at lower E:T ratios (25% at 1:1 ), and had improved specificity when the CTL were tested against malignant and non-malignant controls. To further enhance the level of cytotoxicity we tried to increase the immunostimulatory ability of dendritic cells by maturing them. Subsequent to pulsing the cells with tumor lysate they were matured over night in the presence of monocyte conditioned media. At at 1:1 ratio we increased cytotoxicity levels from undetectable to 30-50%. Together this data suggests that we can generate potent cytotoxic responses to CML cells, and that by manipulating the antigen or dendritic cells we can induce responses at very low E:T ratios. These studies are ongoing.

AB - Dendritic cells are potent antigen presenting cells, which are integral to the initiation of T cell immunity. The ability to culture these cells in vitro has lead to exciting developments in the area of immunotherapy. We undertook the following study to determine if we could induce CTL responses to CML tumor cells, and then examined ways to improve levels of cytotoxicity. Chronic myelogenous leukemia is one of the first hématologie diseases with a defined cytogenetic marker. Initially we generated DC from PBMC, that were collected for autologous transplantation, by culturing adherent cells in the presence of IL-4 and OM-CSF. After 7 days the resultant dendritic cells were harvested and utilized to prime T cells. In brief, PBMC were stimulated in the presence of dendritic cells pulsed with tumor cell lysate from a CML cell line (SK562). After 7 days the cells were restimulated with another round of dendritic cells and lysate. After a further 7 days the resultant primed cells were harvested, counted and utilized in an LDH based cytotoxicity assay. We found we could generate cytotoxicity (12-75%) at a high (10:1) effector (primed cells) to target (SK562 cells) cell ratio. We were able to improve the level and consistency of cytotoxicity (60-63%) at the same E:T ratios by utilizing either whole protein or RNA from the SK562 cell line as a source of antigen. We were also able to generate appreciable cytotoxicity at lower E:T ratios (25% at 1:1 ), and had improved specificity when the CTL were tested against malignant and non-malignant controls. To further enhance the level of cytotoxicity we tried to increase the immunostimulatory ability of dendritic cells by maturing them. Subsequent to pulsing the cells with tumor lysate they were matured over night in the presence of monocyte conditioned media. At at 1:1 ratio we increased cytotoxicity levels from undetectable to 30-50%. Together this data suggests that we can generate potent cytotoxic responses to CML cells, and that by manipulating the antigen or dendritic cells we can induce responses at very low E:T ratios. These studies are ongoing.

UR - http://www.scopus.com/inward/record.url?scp=33748559119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748559119&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748559119

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -